Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Women With Dense Breasts Are at Higher Risk for Cancer
Atossa Genetics' New 'Pap Smear for the Breast' Test Can Spot Signs of Precancerous Changes Long Before Cancer Occurs, Helping to Protect These Women From Cancer

SEATTLE, WA -- (Marketwire) -- 02/04/13 -- Atossa Genetics, Inc. (NASDAQ: ATOS) announced that its new ForeCYTE Breast Health System addresses the problem of detecting not only cancer, but also the early cellular changes that lead to cancer, in women with dense breasts.

Numerous studies have shown that women with denser breast tissue, and thus more gland tissue and less fatty tissue, are at higher risk for breast cancer. Moreover, as the American Cancer Society (ACS) explains, "Dense breast tissue can also make it harder for doctors to spot problems on mammograms." (ACS Guidelines.)

This is why five states -- California, Texas, New York, Connecticut and Virginia -- have passed legislation requiring that women whose mammograms show dense breasts must be notified of this fact, and several other states and the U.S. Congress are considering such legislation. For instance, the New York law, which took effect January 19, 2013, states that mammography patients with dense breasts must be told: "Your mammogram shows that your breast tissue is dense. Dense breast tissue is very common and is not abnormal. However, dense breast tissue can make it harder to find cancer on a mammogram and may also be associated with an increased risk of breast cancer."

One key study highlights those risks. Scientists at the University of California, San Francisco examined aspirated fluid from the breasts of 2,700 women between the ages of 25 to 65. This fluid contains duct cells, which are responsible for more than 90 percent of breast cancers. The study found that women with dense breasts were more than four times more likely than women without dense breasts to have a condition called atypical hyperplasia -- in which the cells seem to grow too quickly and pile up on each other. These atypical cells represent the first steps on the path to cancer. As a result, spotting these cells is not only key to detecting the risk of cancer in these women; it also opens the door to treating the condition and halting the progression to cancer.

"It is vital that we understand the limits of mammography and give women a better test -- one that is capable of detecting the earliest signs of precancer," said Steven C. Quay, M.D., Ph.D., FCAP, Atossa Genetics' Chairman of the Board and Chief Executive Officer.

In January, Atossa Genetics launched such a diagnostic: the ForeCYTE Breast Health Test. The test, cleared by the U.S. Food & Drug Administration, uses a breast pump called the Mammary Aspirate Specimen Cytology Test (MASCT) to painlessly collect miniscule amounts of fluid from the milk ducts in women's breasts, analyzes the duct cells for hyperplasia and other abnormalities, and analyzes for genetic mutations.

In essence, this test is like a Pap smear for cancer, spotting the earliest cellular warnings up to eight years before cancer can be detected by any other method. Women with dense breasts, therefore, could be monitored every year or so for signs of atypical hyperplasia. As long as the results come back negative, these women could lead normal lives without fear of cancer. But if hyperplasia is detected, women could be treated to reverse the condition.

"Just as Pap smears have reduced cervical cancer rates by over 75 percent, becoming the most successful screening test in medicine, this test can detect the precursor changes that lead to breast cancer -- and make prevention possible," says Quay. "We believe this test should be mandatory for women with dense breasts."

To use Atossa's ForeCYTE Breast Health System, see your doctor. The Atossa test is being distributed to health care providers nationwide by Clarity Women's Health (a division of Diagnostic Test Group, LLC) of Boca Raton, Florida. (See press release.)

For background and additional information on breast density legislation, see WSJ online.

About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks set forth in Atossa's filings with the U.S. Securities and Exchange Commission, including the Registration Statement on Form S-1 filed with the SEC on January 28, 2013. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2219020

Contact:

Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP
Chairman, President and CEO of Atossa Genetics and
Director of the National Reference Laboratory for Breast Health
800-351-3902
Email Contact

Adam Holdsworth (Investor Relations)
Dian Griesel Inc. (DGI)
212-825-3210
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
This is the third in a series of cloud predictions for 2015, starting with When the Walls Come Down, which predicted that workload migration (into the cloud) costs would drop by more than 50% in 2015; then continuing with The Cloud Startup Ecosystem Explosion, which predicted the impac...
Cloud computing in the form of Infrastructure-as-a-Service (IaaS) has revolutionized the expectations of IT. Infrastructure that used to take weeks to months to provision is now available in minutes. Moreover, most of the traditional drawbacks associated with infrastructure have disap...
Kirk Byers at SDN Central writes frequently on the topic of DevOps as it relates (and applies) to the network and recently introduced a list of seven DevOps principles that are applicable in an article entitled, "DevOps and the Chaos Monkey. " On this list is the notion of reducing var...
General Electric (GE) has been a household name for more than a century, thanks in large part to its role in making households easier to run. Starting with the light bulb invented by its founder, Thomas Edison, GE has been selling devices (“things”) to consumers throughout its 122-year...
With the growing number of CSS Preprocessors like LESS, Sass, Turbine, Stylus and Swith CSS to name a few, it’s hard to decide which to choose for your project, and which will provide the best CSS authoring. Rather than focus on evaluating every CSS Preprocessor (that would simply take...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE